Sotorasibu price forecast and drug purchasing guide in 2024

Sotorasib, this targeted inhibitor specially developed for patients with advanced non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations, has attracted much attention since its introduction. KRAS G12CMutation is a major problem in the treatment of lung cancer. Due to its unique protein structure, there has been a long-term lack of effective targeted drugs. The emergence of sotoracib has undoubtedly brought new treatment hope to these patients. It precisely binds to the KRAS G12C mutant protein and effectively inhibits its activity, thus blocking the proliferation and spread of cancer cells. It has become the world's first approved KRAS G12C targeted therapy drug. Clinical trial results have also fully verified its significant efficacy. Especially for patients who have failed or relapsed after multiple lines of treatment, sotorasiib undoubtedly provides a new treatment option.

However, for domestic patients, sotorasibu is not yet officially on the market, so it cannot be purchased directly through formal channels. At the same time, because its medical insurance reimbursement policy has not yet been clarified, patients are also very concerned about the price of this drug. According to current market information, the original drug of sotorasibu has been launched in foreign countries such as Europe and Hong Kong, China, but the price is high, usually as high as tens of thousands of yuan per box, which is undoubtedly a large expense for ordinary patient families.

In order to reduce the financial burden on patients, some countries and regions have launched generic versions of sotorasibu. Among them, the prices of generic drugs in Laos are relatively close to the people. For example, the generic drugs of sotoraxibu produced by Lucius and Daxiong Pharmaceutical are currently priced at about more than 1,000 yuan to more than 2,000 yuan per box. These generic drugs are highly similar to the original drugs in terms of drug ingredients and efficacy, but their prices are significantly lower, providing a more economical option for patients who require long-term treatment.